Le Lézard
Classified in: Health, Business
Subjects: CON, FVT

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 4, 2023 at 8:00 am to 9:30 am ET.

The presentations by IDEAYA management and key opinion leaders will showcase scientific insights and clinical development opportunities across IDEAYA's synthetic lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, GSK101/IDE705 (Pol Theta Helicase) in Phase 1, and the Werner Helicase program for which an IND submission is planned for 2024. In addition, IDEAYA will highlight its next generation initiatives for MTAP-deletion, that include a wholly-owned program where a development candidate nomination is targeted in 2024 and multiple first-in-class clinical combination opportunities. The IDEAYA Investor R&D Day Webcast agenda will be the following:

Agenda Topics

Key Opinion Leader Presenters

Investor R&D Day Webcast Presentation and Registration Information

IDEAYA's Investor R&D Day webcast presentation will be available on the company's website, at its Investor Relations portal (https://ir.ideayabio.com/) in advance of the investor webcast presentation at approximately 6:00 am ET.

Registration is available at https://ir.ideayabio.com/events or https://lifescievents.com/event/ideaya/.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality ? which represents an emerging class of precision medicine targets. 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, (i) statements related to participation in, presentation at, and/or content of certain investor relations events, (ii) timing of an IND submission for the Werner Helicase program, and (iii) timing of development candidate nomination for next generation initiatives. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on November 7, 2023 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
[email protected]

SOURCE IDEAYA Biosciences, Inc.

These press releases may also interest you

at 20:21
OKX, a leading Web3 technology company, has issued updates for March 2, 2024. OKX Introduces Exclusive 'Babylon Pioneer Pass Event' in Collaboration with Babylon, Offering Free Pioneer Pass NFT Minting for the First 100,000 Users Who Stake on...

at 20:20
The Board of Barrick Gold Corporation is deeply saddened by the passing of the Chairman of its International Advisory Board and former member of the Barrick Board of Directors, the Right Honorable Brian Mulroney, on February 29, 2024. Prime...

at 20:06
The government of Québec has issued today an Information Bulletin announcing a three-year postponement of the rule limiting access to the non-refundable tax credit for labour-sponsored funds....

at 20:05
Brookfield Business Partners announced today the filing of its 2023 annual reports, including its audited financial statements for the year ended December 31, 2023, on Forms 20-F with the SEC on EDGAR as well as with the Canadian securities...

at 20:00
Toronto Hydro Corporation (the Corporation) today announced its consolidated financial and operating results for the year ended December 31, 2023....

at 20:00
The "Diversity and Inclusion (D&I) - Global Strategic Business Report" report has been added to  ResearchAndMarkets.com's offering. Global Diversity and Inclusion (D&I) Market to Reach $24.4 Billion by 2030The global market for Diversity and...

News published on and distributed by: